Could your own tumor cells fight cancer? new trial tests TIL therapy
NCT ID NCT06488950
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a personalized therapy where immune cells (TILs) are taken from a patient's own tumor, multiplied in a lab, and infused back into the body to attack the cancer. The study includes both natural and gene-edited TILs and enrolls 30 adults with advanced solid tumors who have exhausted standard treatments. The main goal is to check safety, with early signs of tumor shrinkage also being measured.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tumor-infiltrating lymphocytes (TILs) - either natural or gene-edited
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early, small trial (30 people) focused on safety, so it may not show strong anti-tumor effects. Side effects from the lymphodepletion and TIL infusion could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Third Affiliated Hospital of Naval Medical University
RECRUITINGShanghai, China
Contact
Contact
Contact